Trevi Therapeutics (Nasdaq: TRVI) announced management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 9:20 a.m. ET.
Jennifer Good, President and CEO, and David Hastings, CFO, will speak and hold investor meetings during the virtual conference Feb 25–26. Trevi is a clinical-stage biopharmaceutical developing Haduvio (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and refractory chronic cough.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – TRVI
-2.40%
-2.40%Session close to close
In the Feb 17 session, TRVI declined 2.40%, reflecting a moderate negative market reaction.
This announcement highlights Trevi’s participation in a major healthcare investor conference, with a...
Analysis
This announcement highlights Trevi’s participation in a major healthcare investor conference, with a fireside chat on February 25, 2026. It offers management another platform to discuss Haduvio’s development in IPF chronic cough, non-IPF ILD, and RCC, following positive Phase 2b data published in JAMA on Jan 22, 2026. Recent filings also show several large institutional holders above 5%. Investors may focus on any new clinical timelines, partnership commentary, or financing posture discussed during the event.
Reported Q3 2025 net loss and outlined cash position and development plans.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent Trevi news has often been clinically or strategically positive, but share reactions have been mixed, with several positive updates followed by negative price moves.
Recent Company History
Over the last few months, Trevi reported multiple clinical and corporate milestones. On Jan 22, 2026, Phase 2b CORAL data in IPF chronic cough published in JAMA showed statistically significant cough reduction, and shares rose 6.21%. Prior strategic updates on Jan 8, 2026 about moving Haduvio into Phase 3 and planning an RCC Phase 2b led to a -4.27% move. Management changes, including a new CFO announced on Dec 4, 2025, and Q3 2025-11-13 earnings also saw modest declines, underscoring uneven reactions to otherwise constructive developments.
Key Terms
clinical-stage biopharmaceutical, investigational therapy, oral nalbuphine er, idiopathic pulmonary fibrosis (ipf), +2 more
6 terms
clinical-stage biopharmaceuticalmedical
"Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing..."
A clinical-stage biopharmaceutical is a company that is developing medicines or biological treatments that are currently being tested in people in clinical trials to assess safety and effectiveness. For investors it signals a higher-risk, higher-reward profile: progress through human testing and regulatory milestones can sharply increase value if results are positive, while failed trials can wipe out expected future revenue — like a prototype that must prove it works before it can be sold widely.
investigational therapymedical
"developing the investigational therapy Haduvio™ (oral nalbuphine ER)..."
An investigational therapy is a drug, biological product, or medical treatment that is being tested in clinical trials but has not yet received regulatory approval for general use. Investors track these programs because trial results determine whether the therapy can reach patients and produce revenue; think of it as a prototype being validated — successful trials can boost a company’s value, while failures can sharply lower it.
oral nalbuphine ermedical
"Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough..."
An oral nalbuphine ER is a slow‑release pill form of nalbuphine, an opioid pain medicine that activates some pain‑blocking pathways while dampening others, which can lower certain side effects and abuse risk compared with traditional opioids. For investors, it signals a product with potential market demand for longer‑lasting, outpatient pain control, but its commercial value depends on clinical benefits, regulatory approval, patent protection and how payers and prescribers view its safety and cost — like a timed-release version of a familiar pain drug.
idiopathic pulmonary fibrosis (ipf)medical
"chronic cough in patients with idiopathic pulmonary fibrosis (IPF)..."
A chronic lung disease in which the tissue of the lungs gradually becomes scarred and stiff, making it harder to breathe and get enough oxygen. For investors, IPF matters because it drives demand for treatments, shapes the commercial opportunity and clinical trial risk for drug developers, and can influence a company’s regulatory milestones and long‑term revenue potential; think of it as a market shaped by urgent medical need and high development risk.
interstitial lung disease (non-ipf ild)medical
"non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough..."
A group of lung conditions that inflame or scar the thin tissue between air sacs, excluding idiopathic pulmonary fibrosis (IPF). Think of the lungs’ fine internal scaffold becoming thick or stiff, which makes breathing less efficient; different causes and severities fall under this label. Investors watch non‑IPF ILD because it defines patient populations, treatment needs, clinical trial design, and potential market size for therapies and diagnostics.
refractory chronic cough (rcc)medical
"non-IPF ILD), and refractory chronic cough (RCC), today announced..."
Refractory chronic cough is a long-lasting cough that continues for months despite standard treatments and after known causes have been evaluated and managed. For investors, it represents a clear unmet medical need—like a smoke alarm that keeps sounding after the fire is out—which can drive demand for new therapies, influence clinical trial activity, shape regulatory attention, and create commercial opportunities in diagnostics and specialty medicines.
Fireside chat with management on February 25, 2026, at 9:20 a.m. ET
NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and David Hastings, Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, at 9:20 a.m. ET. Held virtually from February 25-26, Ms. Good and Mr. Hastings will also participate in investor meetings with attendees of the event. This fireside chat and meetings will be available for conference attendees.
About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.
Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~150,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.
RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
When will Trevi Therapeutics (TRVI) present at the Oppenheimer conference on February 25, 2026?
Trevi will present in a fireside chat on February 25, 2026 at 9:20 a.m. ET. According to the company, the session is virtual and management will also hold investor meetings with conference attendees during Feb 25–26.
Who from Trevi Therapeutics (TRVI) will speak at the Oppenheimer 36th Annual Healthcare Life Sciences Conference?
Jennifer Good, President and CEO, and David Hastings, CFO will participate in the fireside chat. According to the company, both executives will also meet with investors attending the virtual event on Feb 25–26.
Will the Trevi Therapeutics (TRVI) fireside chat at Oppenheimer be available to virtual attendees?
Yes, the fireside chat and investor meetings will be available to conference attendees. According to the company, the event is held virtually February 25–26, enabling attendees to access the presentation and meetings online.
What program will Trevi Therapeutics (TRVI) discuss at the Oppenheimer conference on February 25, 2026?
Trevi will discuss its clinical-stage program for Haduvio (oral nalbuphine ER) targeting chronic cough in IPF, non-IPF ILD, and refractory chronic cough. According to the company, management will cover program updates during the fireside chat.
How can investors arrange meetings with Trevi Therapeutics (TRVI) during the Oppenheimer conference?
Investors can schedule meetings with Trevi management through conference attendee arrangements. According to the company, Jennifer Good and David Hastings will participate in investor meetings during the virtual Feb 25–26 event.
